Rolf F. Barth

Sources

Sources are listed once and connected to each accepted claim they support. Excerpts preserve the source language used in the review.

1. [1]

   OSU Pathology - Barth

   17 source claims · Reviewed Sep 9, 2026

   Show supporting evidence

   Biographical context: 1970 Anatomic Pathology, American Board of Pathology

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Degree: MD

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Education record: 1959 A.B., Cornell University, Ithaca, New York

   1959 A.B., Cornell University, Ithaca, New York

   Education record: 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York

   1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York

   Identity: Rolf F. Barth, MD

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Professional role: 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio.

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Professional role: 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio.

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Professional role: 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio.

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Professional role: Academy Professor

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Professional role: I have had clinical responsibilities as a Pathologist on the Autopsy Service.

   I have had clinical responsibilities as a Pathologist on the Autopsy Service.

   Professional role: Pathologist

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Professional role: Professor

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Professional role: Professor Emeritus

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Research interests: A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy.

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Research interests: Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors.

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Research interests: I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model.

   Rolf F. Barth, MD Professor Emeritus Phone: [contact withheld] E-mail: Email Dr. Barth Office Location: 4189 Graves Hall 333 W. 10th Ave Columbus, OH 43210 Biography Publications Biography Biosketch I have been involved in cancer research for the past 35 years. The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers. BNCT is a noninvasive therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors and recurrent head and neck cancer. It is a two-step procedure: first, the patient is injected with a non-radioactive tumor localizing boron-10–containing drug that has a high propensity to capture slow neutrons. The cross section of the boron-10 is one to two thousand times greater than that of the other elements normally present in tissues. In the second step, the patient is radiated with epithermal neutrons, which after losing energy as they penetrate tissue, are absorbed by the boron-10, which subsequently emits high-energy radiation, resulting in a biologically destructive nuclear reaction. I have utilized my training in tumor immunology to focus on the use of monoclonal antibodies (MoAbs), directed against specific molecular targets such as the epidermal growth factor receptor (EGFR), as boron delivery agents for BNCT to treat malignant brain tumors using a rat brain tumor model. Another component of my BNCT research has focused on the evaluation of low molecular weight boron compounds and optimization of their delivery for the treatment of brain tumors. A new area of research over the past 8 years has focused on another chemoradiotherapeutic approach for the treatment of brain tumors that combines administration of the anti-cancer drugs carboplatin or cisplatin directly to the site of the brain tumor combined with radiotherapy. This research has been funded by a variety of sources, including the National Institutes of Health, the American Cancer Society, the Department of Energy, and numerous private foundations. In addition to the research described above, I have had clinical responsibilities as a Pathologist on the Autopsy Service. Board Certifications 1970 Anatomic Pathology, American Board of Pathology Academic and Medical Appointments 2016-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus Ohio. 2013-2016 Professor Emeritus, Department of Pathology, The Ohio State University, Columbus Ohio. 1979-2013 Professor, Department of Pathology, The Ohio State University, Columbus Ohio. Education and Training 1964 M.D., College of Physicians & Surgeons, Columbia University, New York, New York 1959 A.B., Cornell University, Ithaca, New York

   Research interests: The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers.

   The primary focus of my research has been in the field of boron neutron capture therapy (BNCT) for the treatment of malignant gliomas, one of the most malignant of human cancers.